Related Experiment Video
Updated: Jul 14, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Frontotemporal lobar degeneration: recent progress in antemortem diagnosis
1Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Acta Neuropathologica
|June 2, 2007
Summary
Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease affecting behavior and language. This review details biomarkers for diagnosing FTLD subtypes, aiding targeted treatment development.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disorder causing behavioral and language impairments.
- FTLD is pathologically classified into tau-positive (e.g., Pick bodies, corticobasal degeneration) and tau-negative (e.g., TDP-43 inclusions) subtypes.
- Developing etiological treatments requires accurate diagnosis of specific FTLD subtypes.
Purpose of the Study:
- To review diagnostic biomarkers for Frontotemporal lobar degeneration (FTLD).
- To identify features aiding in the in-vivo diagnosis of distinct FTLD pathological subtypes.
- To support the development of targeted therapies and efficacy assessments in clinical trials.
Main Methods:
- Review of epidemiologic, clinical, and neuropsychological features.
- Analysis of neuroimaging and cerebrospinal fluid (CSF) biomarkers.
- Correlation of clinical/biomarker data with pathological classifications of FTLD.
Main Results:
- Specific clinical and biomarker profiles are associated with tau-positive and tau-negative FTLD subtypes.
- Epidemiologic data provides context for FTLD prevalence and risk factors.
- Neuroimaging and CSF biomarkers show potential for differentiating FTLD pathologies.
Conclusions:
- Accurate diagnosis of FTLD subtypes is crucial for targeted treatment.
- Biomarkers are essential for identifying specific FTLD pathologies during life.
- This review consolidates features to aid clinical diagnosis and therapeutic development for FTLD.
More Related Videos
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.